Abvc Biopharma Stock Today

ABVC Stock  USD 0.66  0.01  1.54%   

Performance

OK

 
Weak
 
Strong

Odds Of Distress

High

 
High
 
Low
ABVC Biopharma is trading at 0.66 as of the 19th of March 2025, a 1.54 percent increase since the beginning of the trading day. The stock's open price was 0.65. ABVC Biopharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of October 2017
Category
Healthcare
Classification
Health Care
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. Abvc Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 23.69 M outstanding shares of which 257.94 K shares are presently shorted by private and institutional investors with about 0.37 trading days to cover. More on ABVC Biopharma

Moving against ABVC Stock

  0.71VCEL Vericel Corp OrdPairCorr
  0.67VCYT VeracytePairCorr
  0.64DNLI Denali TherapeuticsPairCorr
  0.6A Agilent TechnologiesPairCorr
  0.5VERA Vera TherapeuticsPairCorr
  0.47DRTS Alpha Tau MedicalPairCorr

ABVC Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.01150.0121
Notably Down
Pretty Stable
Total Current Liabilities7.2 M6.8 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total915.9 K493.5 K
Way Up
Very volatile
Total Assets17.5 M16.7 M
Sufficiently Up
Slightly volatile
Total Current Assets1.4 M1.9 M
Way Down
Slightly volatile
Debt Levels
ABVC Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ABVC Biopharma's financial leverage. It provides some insight into what part of ABVC Biopharma's total assets is financed by creditors.
Liquidity
ABVC Biopharma currently holds 2.28 M in liabilities with Debt to Equity (D/E) ratio of 0.34, which is about average as compared to similar companies. ABVC Biopharma has a current ratio of 2.63, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ABVC Biopharma's use of debt, we should always consider it together with its cash and equity.

Change In Working Capital

1.18 Million
ABVC Biopharma (ABVC) is traded on NASDAQ Exchange in USA. It is located in 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538 and employs 16 people. ABVC Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.41 M. ABVC Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 23.69 M outstanding shares of which 257.94 K shares are presently shorted by private and institutional investors with about 0.37 trading days to cover. ABVC Biopharma currently holds about 2.99 M in cash with (4.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check ABVC Biopharma Probability Of Bankruptcy
Ownership Allocation
ABVC Biopharma holds a total of 23.69 Million outstanding shares. ABVC Biopharma retains substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check ABVC Ownership Details

ABVC Stock Institutional Holders

InstituionRecorded OnShares
Bank Of America Corp2024-12-31
81.0
Ubs Group Ag2024-12-31
10.0
Honkamp Krueger Financial Services Inc2024-12-31
144 K
Geode Capital Management, Llc2024-12-31
79.3 K
Vanguard Group Inc2024-12-31
46.9 K
Citadel Advisors Llc2024-12-31
40.7 K
Xtx Topco Ltd2024-12-31
34.4 K
Northern Trust Corp2024-12-31
19.1 K
Virtu Financial Llc2024-12-31
15.9 K
State Street Corp2024-12-31
12.9 K
Two Sigma Securities, Llc2024-12-31
12.6 K
View ABVC Biopharma Diagnostics

ABVC Biopharma Historical Income Statement

At present, ABVC Biopharma's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 364.7 K, whereas Selling General Administrative is forecasted to decline to about 5 M. View More Fundamentals

ABVC Stock Against Markets

ABVC Biopharma Corporate Management

TsungShann JiangMember OfficerProfile
Leeds ChowChief OfficerProfile
Howard MDPres CEOProfile
ChiHsin KingChief OfficerProfile
Uttam PatilChief OfficerProfile
Eugene JiangChairman OfficerProfile

Already Invested in ABVC Biopharma?

The danger of trading ABVC Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ABVC Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ABVC Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ABVC Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.81)
Revenue Per Share
0.051
Quarterly Revenue Growth
23.507
Return On Assets
(0.25)
Return On Equity
(1.02)
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.